PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

VJOncology

1 year
431 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL. Dr Armstrong shares details of the PROPHECY trial (NCT02269982), which is investigating AR-V7 on circulating tumor cells as a prospective predictor in men with metastatic castration-resistant prostate cancer (mCRPC).
Up Next Autoplay